InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (13 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
13
T+90 hit rate
0%
T+90 mean return
-21.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Dowden Nathan J, Chief Operating Officer. Officer active across 1 company, notably Entrada Therapeutics, Inc.. Aggregated, 24 filings have been published. Breakdown: 0 buy · 13 sells. Total volume traded: €522k. Activity tracked since 1 March 2022. The latest transaction was filed on 4 May 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations24 total
15,000 shares@ US$1.740.0090% mcap16.0% of flowCommon StockSEC:0001873392-26-000004
15,000 shares@ US$1.740.0090% mcap16.0% of flowCommon StockSEC:0001873392-26-000004:0
60,800 shares0Common StockSEC:0001689375-25-000013:0
847 shares@ US$16.002.0% of flowCommon StockSEC:0001689375-24-000056:0
399 shares@ US$15.19470.9% of flowCommon StockSEC:0001689375-24-000054:0
483 shares@ US$15.76111.1% of flowCommon StockSEC:0001689375-24-000051:0
20,000 shares@ US$1.745.2% of flowCommon StockSEC:0001689375-24-000048:0
1,826 shares@ US$12.32133.4% of flowCommon StockSEC:0001689375-24-000007:0
33,100 shares0Common StockSEC:0001689375-24-000004:0
14,200 shares0Common StockSEC:0001689375-23-000061:0
3,200 shares@ US$18.00168.6% of flowCommon StockSEC:0001689375-23-000047:0
8,885 shares@ US$14.935720.1% of flowCommon StockSEC:0001689375-23-000042:0
14,200 shares0Common StockSEC:0001689375-23-000026:0
28,400 shares0Common StockSEC:0001689375-23-000012:0
2,100 shares@ US$24.04538.4% of flowCommon StockSEC:0001689375-22-000040:0
3,034 shares@ US$20.104310.1% of flowCommon StockSEC:0001689375-22-000038:0
905 shares@ US$18.07352.8% of flowCommon StockSEC:0001689375-22-000036:0
1,329 shares@ US$15.323.5% of flowCommon StockSEC:0001689375-22-000032:0
3,275 shares@ US$15.12588.3% of flowCommon StockSEC:0001689375-22-000029:0
100 shares@ US$15.010.2% of flowCommon StockSEC:0001689375-22-000027:0
912 shares@ US$15.14722.3% of flowCommon StockSEC:0001689375-22-000018:0
5,632 shares0Common StockSEC:0001104659-22-097873:0
7,714 shares@ US$13.000.038% mcap68.0% of flowCommon StockSEC:0001104659-22-075788:0
11,263 shares0Common StockSEC:0001104659-22-030009:0
24 of 24 declarations
About Dowden Nathan J
Nathan J. Dowden is the President and Chief Operating Officer of Entrada Therapeutics, Inc. In this role, he oversees the daily operations of the company and ensures the implementation of the business strategy. Dowden plays a key role in business development and process optimization, thereby contributing to Entrada's growth. His leadership is essential in ensuring the organization's success.
